Healthcare provider profile · identity verified

Henry S Juan, MD

Internal Medicine · VANCOUVER, WA · NPI 1952474009

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	683	204
Lisinopril	Lisinopril	423	135
Losartan Potassium	Losartan Potassium	343	101
Amlodipine Besylate	Amlodipine Besylate	290	88
Levothyroxine Sodium	Levothyroxine Sodium	247	66
Metoprolol Succinate	Metoprolol Succinate	167	49
Trazodone Hcl	Trazodone Hcl	167	57
Tamsulosin Hcl	Tamsulosin Hcl	162	58
Albuterol Sulfate Hfa	Albuterol Sulfate	159	69
Gabapentin	Gabapentin	149	48
Metformin Hcl	Metformin Hcl	141	45
Metoprolol Tartrate	Metoprolol Tartrate	137	42
Metformin Hcl Er	Metformin Hcl	128	35
Atenolol	Atenolol	119	33
Pantoprazole Sodium	Pantoprazole Sodium	115	42
Pradaxa	Dabigatran Etexilate Mesylate	112	34
Glipizide	Glipizide	110	39
Allopurinol	Allopurinol	109	26
Hydrochlorothiazide	Hydrochlorothiazide	107	34
Rosuvastatin Calcium	Rosuvastatin Calcium	100	29
Sertraline Hcl	Sertraline Hcl	97	31
Furosemide	Furosemide	91	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	91	39
Oxycodone Hcl	Oxycodone Hcl	87	29
Potassium Chloride	Potassium Chloride	87	24
Simvastatin	Simvastatin	85	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	76	27
Omeprazole	Omeprazole	63	24
Warfarin Sodium	Warfarin Sodium	62	16
Propranolol Hcl	Propranolol Hcl	55	16
Ondansetron Odt	Ondansetron	54	18
Clopidogrel	Clopidogrel Bisulfate	52	19
Humulin N	Insulin Nph Human Isophane	51	17
Spironolactone	Spironolactone	51	16
Finasteride	Finasteride	47	16
Buspirone Hcl	Buspirone Hcl	45	15
Duloxetine Hcl	Duloxetine Hcl	45	13
Pravastatin Sodium	Pravastatin Sodium	43	12
Alendronate Sodium	Alendronate Sodium	39	13
Meloxicam	Meloxicam	38	19
Humulin R	Insulin Regular, Human	37	11
Triamcinolone Acetonide	Triamcinolone Acetonide	37	18
Wixela Inhub	Fluticasone Propion/Salmeterol	37	14
Estradiol	Estradiol	35	16
Fluoxetine Hcl	Fluoxetine Hcl	35	15
Zolpidem Tartrate	Zolpidem Tartrate	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	34	31
Escitalopram Oxalate	Escitalopram Oxalate	33	suppressed
Fluticasone Propionate	Fluticasone Propionate	32	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Mirtazapine	Mirtazapine	32	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	32	suppressed
Pregabalin	Pregabalin	31	13
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	31	suppressed
Donepezil Hcl	Donepezil Hcl	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	29	suppressed
Terazosin Hcl	Terazosin Hcl	29	12
Acyclovir	Acyclovir	27	13
Alvesco	Ciclesonide	27	12
Doxycycline Monohydrate	Doxycycline Monohydrate	27	23
Prednisone	Prednisone	27	15
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Spiriva Respimat	Tiotropium Bromide	24	11
Tramadol Hcl	Tramadol Hcl	24	13
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	21	suppressed
Eliquis	Apixaban	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Torsemide	Torsemide	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Naproxen	Naproxen	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	16	16
Xarelto	Rivaroxaban	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Nitroglycerin	Nitroglycerin	15	12
Cartia Xt	Diltiazem Hcl	14	suppressed
Famotidine	Famotidine	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Latanoprost	Latanoprost	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Morphine Sulfate	Morphine Sulfate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	13	13
Clonazepam	Clonazepam	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Cephalexin	Cephalexin	12	12
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Risperidone	Risperidone	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error